presents

Tumor Board in Sarcoma Tumors 

Live Webinar

AGENDA

Tuesday, January 30, 2018

5:30pm   -   Welcome Remarks                                         

                      Dr. Jonathan C. Trent, MD, PhD

5:35pm   -   What’s New in Sarcoma Treatments   

                     Dr. Jonathan C. Trent, MD, PhD

                   

5:50pm   -   Clinical Case 01 - Instituto Oncologico Heriberto Pieter, DR

                     Presented by IOHP faculty

                     

6:00pm    -  Discussion 

                     Dr. Jonathan C. Trent, MD, PhD, Dr. Breelyn Wilky and participants

6:10pm    -  Clinical Case 02 - HCPA, Brazil

                     Presented by HCPA faculty

6:20pm    -  Discussion 

                     Dr. Jonathan C. Trent, MD, PhD, Dr. Breelyn Wilky and participants 

6:30pm    -   Final Remarks 

                      Dr. Jonathan C. Trent, MD, PhD

 

Meet the Distinguished Speakers

Dr. Jonathan C. Trent, MD, PhD

Professor of Medicine

Associate Director of Clinical Research

Director, Sarcoma Medical Research Program

Director, Musculoskeletal Center

 

Dr. Trent earned his undergraduate degree in chemistry at Southeastern Oklahoma State University and his MD and PhD in cancer biology from The University of Texas Health Science Center. He completed an internship and residency in internal medicine at The University of Texas Health Science Center, and a fellowship in medical oncology at The University of Texas M. D. Anderson Cancer Center while serving as chief fellow. Prior to joining the University of Miami Miller School of Medicine, he held appointments as faculty of the University of Texas Graduate School of Biomedical Sciences at Houston, and associate professor of medicine in the Department of Sarcoma Medical Oncology, Division of Cancer Medicine at the University of Texas M.D. Anderson Cancer Center in Houston. Dr. Trent’s interests are in the clinical and translational research of sarcomas, direct care of sarcoma patients, and education about sarcoma and patient-oriented research. The major focus of his clinical, educational and research efforts are with gastrointestinal stromal tumor (GIST), and all other sarcomas including dermatofibrosarcoma protuberans, myxoid liposarcoma, perivascular endothelial cell sarcoma (PEComa), angiomyolipoma, and rhabdomyosarcoma. The major efforts of Dr. Trent’s research focus on understanding the mechanisms of action and resistance of imatinib in GIST while striving toward improved therapeutic options. His work will involve the use of novel preoperative/postoperative clinical trials, prospectively acquired tumor tissue, cell lines, archival tissue, as well as collaborations with disciplines such as the genomics facility, surgical oncology, pathology, radiology and interventional radiology.

Dr. Breelyn Wilky

Assistant Professor, Sarcoma Program

 

Dr. Breelyn Wilky is a sarcoma medical oncologist at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine in Miami, FL.  She is part of a large multidisciplinary sarcoma team including medical oncologists, surgeons, radiation oncologists, pediatric oncologists, pathologists, radiologists, and interventional radiologists who work together to provide comprehensive care for sarcoma patients.  She spends her time taking care of patients over the age of 18 with all kinds of sarcomas and other bone and soft tissue tumors including desmoid fibromatosis, pigmented villonodular synovitis, gastrointestinal stromal tumors, and giant cell tumor of bone.  She is also a translational researcher who conducts and designs clinical trials for sarcoma patients.  She also works with laboratory researchers to translate the latest findings from bench research into early phase clinical trials.  She is an expert not only in traditional chemotherapy treatments for sarcomas, but also at using modern technology such as gene sequencing and molecular profiling to identify out-of-the-box treatments particularly in targeted therapy.  She is particularly interested in novel immunotherapy approaches for sarcomas.

 

Dr. Wilky received her undergraduate degree in Biology and Music from Bates College in Lewiston, Maine, and attended medical school at the University of Medicine and Dentistry of New Jersey – Robert Wood Johnson Medical School in Piscataway, New Jersey (now Rutgers Medical School.)  She received her MD with Distinction in Research.  She then completed the Osler internship and residency in Internal Medicine at The Johns Hopkins Hospital in Baltimore, Maryland, and stayed there to complete her fellowship in Medical Oncology.  Her honors and awards include election to the Alpha Omega Alpha Honor Medical Society, a recipient of an ASCO/Conquer Cancer Foundation Young Investigator Award in 2012 for her work investigating DDX3 as a novel therapeutic target in Ewing Sarcoma, and was recently selected as the Outstanding Clinical Researcher of the Year for 2017 at Sylvester Comprehensive Cancer Center.